Ask AI

Novel ADC Therapies for Relapsed/Refractory Large B-Cell Lymphoma: Translating the Latest Advances Into Community Oncology Practice

Enhance your clinical decision-making when managing relapsed/refractory DLBCL with the use of ADCs therapies informed by the latest clinical data and guideline recommendations to optimize patient outcomes via downloadable resources, including a live webinar and “Success Strategies” slideset, certified on-demand webcast, and expert-authored commentaries.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from ADC Therapeutics and Pfizer Inc.

ADC Therapeutics

Pfizer, Inc.